²é¿´: 558  |  »Ø¸´: 2
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ygy19901025

ľ³æ (ÖøÃûдÊÖ)

[ÇóÖú] ÉúÎïÀàÕªÒª£¬Çó·­ÒëÓ¢Ò뺺£¬½ð±Ò·îÉÏ

Abstract
Glycogen synthase kinase-3¦Â (GSK-3¦Â), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation. In this study calpain was found to cleave GSK-3¦Â not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38¨CThr-39 and Ile-384¨CGln-385. Furthermore, the cleavage of GSK-3¦Â occurred in tandem with Ser-9 dephosphorylation during cerebellar granule neuron apoptosis. Increasing Ser-9 phosphorylation of GSK-3¦Â by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3¦Â at both N and C termini, whereas non-phosphorylatable mutant GSK-3¦Â S9A facilitated its cleavage. In contrast, Ser-389 phosphorylation selectively inhibited the cleavage of GSK-3¦Â at the C terminus but not the N terminus. Calpain-mediated cleavage resulted in three truncated products, all of which contained an intact kinase domain: ¦¤N-GSK-3¦Â (amino acids 39¨C420), ¦¤C-GSK-3¦Â (amino acids 1¨C384), and ¦¤N/¦¤C-GSK-3¦Â (amino acids 39¨C384). All three truncated products showed increased kinase and pro-apoptotic activity, with ¦¤N/¦¤C-GSK-3¦Â being the most active form. This observation suggests that the GSK-3¦Â C terminus acts as an autoinhibitory domain similar to the N terminus. Taken together, these findings demonstrate that calpain-mediated cleavage activates GSK-3¦Â by removing its N- and C-terminal autoinhibitory domains and that Ser-9 phosphorylation inhibits the cleavage of GSK-3¦Â at both termini. In contrast, Ser-389 phosphorylation inhibits only C-terminal cleavage but not N-terminal cleavage. These findings also identify a mechanism by which site-specific phosphorylation and calpain-mediated cleavage operate in concert to regulate GSK-3¦Â activity.
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ygy19901025

ľ³æ (ÖøÃûдÊÖ)

ÔõôûÈ˻ظ´ÄØ
2Â¥2014-03-13 12:40:31
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wangyuan0929

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ...
ygy19901025: ½ð±Ò+100, ·­ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-03-13 22:11:24
Abstract
ÕªÒª
Glycogen synthase kinase-3¦Â (GSK-3¦Â), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.
ÌÇÔ­ºÏ³Éø¼¤Ã¸-3¦Â£¨GSK-3¦Â£©£¬ÊÇÉñ¾­ÔªµòÍöµÄ¹Ø¼üµ÷¿ØÎïÖÊ£¬»áÊܵ½Ser-9/Ser-389λµãÁ×ËữµÄÒÖÖÆ£¬×î½ü·¢ÏÖËü¿ÉÒÔ±»¸Æµ°°×øÔÚN¶ËÇжϣ¬ÕâÒ»·´Ó¦Ëæºó½«Æä»î»¯¡£
In this study calpain was found to cleave GSK-3¦Â not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38¨CThr-39 and Ile-384¨CGln-385.
±¾Ñо¿Öз¢ÏָƵ°°×ø²»½öÄÜÇжÏGSK-3¦ÂµÄN¶Ë£¬»¹¿ÉÒÔÇпªÆäCÄ©¶Ë£¬²¢È·¶¨ÁËÆäøÇÐλµãΪThr-38/Thr-39ºÍIle-384/Gln-385ÕâÁ½¶Ô°±»ùËá²Ð»ùÖ®¼ä¡£
Furthermore, the cleavage of GSK-3¦Â occurred in tandem with Ser-9 dephosphorylation during cerebellar granule neuron apoptosis.
ÁíÍ⣬GSK-3¦ÂµÄÇжÏÊÇÓëSer-9µÄÈ¥Á×Ëữ¹ý³ÌÒ»Æð£¬ÔÚСÄÔ¿ÅÁ£Éñ¾­ÔªµòÍö¹ý³ÌÖз¢ÉúµÄ¡£
Increasing Ser-9 phosphorylation of GSK-3¦Â by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3¦Â at both N and C termini, whereas non-phosphorylatable mutant GSK-3¦Â S9A facilitated its cleavage.
ͨ¹ýÒÖÖÆÁ×Ëáø1/2A»òÓô¿»¯¹ýµÄ»î»¯Ì¬µÄAkt½øÐÐÔ¤´¦Àí£¬À´Ìá¸ßSer-9µÄÁ×Ëữ³Ì¶È£¬¿ÉÒÔÒÖÖÆ¸Æµ°°×ø½éµ¼µÄGSK-3¦ÂÔÚNÄ©¶ËºÍCÄ©¶Ë·¢ÉúµÄ¶ÏÁÑ£¬È»¶ø²»¿ÉÁ×ËữµÄGSK-3¦ÂÍ»±äÌåS9AÔòÄܹ»´Ù½øÆä¶ÏÁÑ¡£
In contrast, Ser-389 phosphorylation selectively inhibited the cleavage of GSK-3¦Â at the C terminus but not the N terminus.
Ïà±È֮ϣ¬Ser-389µÄÁ×ËữѡÔñÐÔµÄÒÖÖÆÁËGSK-3¦ÂÔÚCÄ©¶ËµÄ¶ÏÁÑ£¬¶ø¶ÔNÄ©¶ËûÓÐÓ°Ïì¡£
Calpain-mediated cleavage resulted in three truncated products, all of which contained an intact kinase domain: ¦¤N-GSK-3¦Â (amino acids 39¨C420), ¦¤C-GSK-3¦Â (amino acids 1¨C384), and ¦¤N/¦¤C-GSK-3¦Â (amino acids 39¨C384).
¸Æµ°°×ø½éµ¼µÄ¶ÏÁѲúÉúÁËÈýÖÖøÇвúÎËüÃǶ¼°üº¬ÁËÍêÕûµÄ¼¤Ã¸½á¹¹Óò£º¦¤N-GSK-3¦Â (°±»ùËá²Ð»ù39¨C420), ¦¤C-GSK-3¦Â (°±»ùËá²Ð»ù1¨C384), ÒÔ¼°¦¤N/¦¤C-GSK-3¦Â (°±»ùËá²Ð»ù39¨C384).
All three truncated products showed increased kinase and pro-apoptotic activity, with ¦¤N/¦¤C-GSK-3¦Â being the most active form.
ËùÓÐÕâÈýÖÖøÇвúÎïÏÔʾ³öÁ˸ü¸ßµÄ¼¤Ã¸»îÐÔÒÔ¼°´ÙµòÍö»îÐÔ£¬ÆäÖÐ ¦¤N/¦¤C-GSK-3¦Â »îÐÔ×î¸ß¡£
This observation suggests that the GSK-3¦Â C terminus acts as an autoinhibitory domain similar to the N terminus.
ÕâÒ»ÏÖÏóÏÔʾ³öGSK-3¦ÂµÄCÄ©¶ËÓëNÄ©¶ËÀàËÆ£¬¶¼ÊÇÒ»ÖÖÆð×ÔÎÒÒÖÖÆ×÷ÓõĽṹÓò¡£
Taken together, these findings demonstrate that calpain-mediated cleavage activates GSK-3¦Â by removing its N- and C-terminal autoinhibitory domains and that Ser-9 phosphorylation inhibits the cleavage of GSK-3¦Â at both termini.
×ÛÉÏËùÊö£¬ÕâЩ·¢ÏÖÏÔʾ³ö£º¸Æµ°°×ø½éµ¼µÄ¶ÏÁÑÒÆ³ýÁËNÄ©¶ËºÍCÄ©¶ËµÄ×ÔÎÒÒÖÖÆ½á¹¹Óò£¬´Ó¶ø»î»¯ÁËGSK-3¦Â£¬Ser-9µÄÁ×Ëữ×÷ÓÃÒÖÖÆÁËGSK-3¦ÂµÄÁ½¸öÄ©¶Ë·¢ÉúµÄ¶ÏÁÑ·´Ó¦¡£
In contrast, Ser-389 phosphorylation inhibits only C-terminal cleavage but not N-terminal cleavage.
Ïà±È֮ϣ¬Ser-389µÄÁ×ËữֻÄÜÒ»Ö±CÄ©¶ËµÄ¶ÏÁÑ£¬¶ø²»ÒÖÖÆNÄ©¶Ë¶ÏÁÑ¡£
These findings also identify a mechanism by which site-specific phosphorylation and calpain-mediated cleavage operate in concert to regulate GSK-3¦Â activity.
ÕâЩ·¢ÏÖ»¹È·¶¨ÁËÒ»¸öλµãÌØÒìÐÔÁ×Ëữ×÷Óú͸Ƶ°°×ø½éµ¼µÄ¶ÏÁÑ×÷ÓÃÒ»Æëµ÷½ÚGSK-3¦ÂµÄ»îÐÔµÄ×÷ÓûúÖÆ¡£
3Â¥2014-03-13 14:48:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ygy19901025 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á +3 Ymlll 2026-03-18 4/200 2026-03-18 18:57 by yeahyou
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤µ÷¼Á 324·Ö +7 llllkkkhh 2026-03-18 7/350 2026-03-18 17:18 by 216µÄ¹ÊÊÂ
[¿¼ÑÐ] 26µ÷¼Á/²ÄÁÏ/Ó¢Ò»Êý¶þ/×Ü·Ö289/ÒѹýAÇøÏß +7 ²½´¨¿á×Ï123 2026-03-13 7/350 2026-03-18 17:12 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] ²ÄÁÏרҵÇóµ÷¼Á +3 hanamiko 2026-03-18 3/150 2026-03-18 16:30 by 30660438
[¿¼ÑÐ] 299Çóµ÷¼Á +5 ¡÷С͸Ã÷* 2026-03-17 5/250 2026-03-18 11:49 by ¾¡Ë´Ò¢1
[¿¼²©] »·¾³ÁìÓòÈ«¹úÖØµãʵÑéÊÒÕÐÊÕ²©Ê¿1-2Ãû +3 QGZDSYS 2026-03-13 5/250 2026-03-18 11:13 by QGZDSYS
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á ×Ü·Ö331 +3 ZY-05 2026-03-13 3/150 2026-03-18 10:58 by macy2011
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼²©] 26É격 +4 °ËÑ®ËÙÀÀ 2026-03-16 4/200 2026-03-17 13:00 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] Ò»Ö¾Ô¸£¬¸£ÖÝ´óѧ²ÄÁÏר˶339·ÖÇóµ÷¼Á +3 ľ×ÓmomoÇàÕù 2026-03-15 3/150 2026-03-17 07:52 by laoshidan
[¿¼ÑÐ] ¶«ÄÏ´óѧ364Çóµ÷¼Á +5 JasonYuiui 2026-03-15 5/250 2026-03-16 21:28 by ľ¹Ï¸à
[¿¼ÑÐ] 326Çóµ÷¼Á +4 ŵ±´¶û»¯Ñ§½±êéê 2026-03-15 7/350 2026-03-16 17:11 by ŵ±´¶û»¯Ñ§½±êéê
[¿¼ÑÐ] 304Çóµ÷¼Á +5 ËØÄê¼ÀÓï 2026-03-15 5/250 2026-03-16 17:00 by ÎҵĴ¬Îҵĺ£
[¿¼ÑÐ] 26¿¼ÑÐÒ»Ö¾Ô¸ÖйúʯÓÍ´óѧ(»ª¶«)305·ÖÇóµ÷¼Á +3 ¼ÎÄêÐÂ³Ì 2026-03-15 3/150 2026-03-15 13:58 by ¹þ¹þ¹þ¹þºÙºÙºÙ
[¿¼ÑÐ] 070305Çóµ÷¼Á +3 mlpqaz03 2026-03-14 4/200 2026-03-15 11:04 by peike
[¿¼ÑÐ] 294Çóµ÷¼Á +3 Zys010410@ 2026-03-13 4/200 2026-03-15 10:59 by zhq0425
[¿¼ÑÐ] Öпƴó²ÄÁÏר˶319Çóµ÷¼Á +3 ÃÏöβÄÁÏ 2026-03-13 3/150 2026-03-14 18:10 by houyaoxu
[¿¼ÑÐ] ÕÐÊÕ0805£¨²ÄÁÏ£©µ÷¼Á +3 18595523086 2026-03-13 3/150 2026-03-14 00:33 by 123%¡¢
[¿¼ÑÐ] 281Çóµ÷¼Á +9 Koxui 2026-03-12 11/550 2026-03-13 20:50 by Koxui
[¿¼ÑÐ] ÍÁľµÚÒ»Ö¾Ô¸276Çóµ÷¼Á£¬¿ÆÑкͼ¼ÄÜÊ®·Ö·á¸»£¬ÇóÐÂÐË·½ÏòµÄµ¼Ê¦ÊÕÁô +3 ÍÁľСÌì²Å 2026-03-12 3/150 2026-03-13 15:01 by JourneyLucky
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û